Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CX516 in Fragile X Syndrome and Autism
NCT00054730Phase 2Completed
- Sponsor
- RespireRx Pharmaceuticals
- Start
- Jun 2002
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Fragile X syndrome (FXS) and Autism Spectrum Disorder (ASD) comparing CX516 with Placebo (2 arms). Primary endpoint: Memory at 4 weeks. Started Jun 2002; status: completed.
02
Drugs
cx516
03
Conditions
Fragile X syndrome (FXS)Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT00054730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00054730.